Amgen and Celltrion biosimilar trastuzumab products considered for PBS listing

Both Amgen and Celltrion’s biosimilar trastuzumab products, Kanjiti® and Herzuma® respectively, were considered by Australia’s PBAC committee for PBS listing and A flagging (substitution).  This follows the May 2019 PBAC recommendations for PBS listing of Mylan and MSD’s biosimilar products.